Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2000062 | 0.89 | TAAR1 (0.50) | NPC1RAB9ASMN1; SMN2TAAR1GPR84 | |
| SCHEMBL144122 | 0.84 | — | — | |
| Water SCHEMBL29498409 | 0.82 | TAAR1 (0.54) | NPC1RAB9ASMN1; SMN2TAAR1GPR84 | |
| SCHEMBL10484395 | 0.81 | TAAR1 (0.58) | NPC1RAB9ASMN1; SMN2TAAR1GPR84 | |
| SCHEMBL15285045 | 0.81 | TAAR1 (0.48) | NPC1RAB9ASMN1; SMN2TAAR1GPR84 | |
| SCHEMBL1258123 | 0.80 | — | — | |
| SCHEMBL144588 | 0.80 | TAAR1 (0.57) | NPC1RAB9ASMN1; SMN2TAAR1GPR84 | |
| Hydrochloric Acid SCHEMBL10484340 | 0.79 | TAAR1 (0.56) | NPC1RAB9ASMN1; SMN2TAAR1GPR84 | |
| SCHEMBL142887 | 0.78 | TAAR1 (0.55) | NPC1RAB9ASMN1; SMN2TAAR1GPR84 | |
| SCHEMBL20689749 | 0.78 | MAOB (0.57) | NPC1RAB9ASMN1; SMN2TAAR1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107056801-B | A kind of synthetic method of 4,5,6,7- thiophane simultaneously [3,2-c] pyridine hydrochloride | 太原理工大学 | 2018-12-28 | — | — | CN | claimed |
| CN-107056801-A | A kind of synthetic method of 4,5,6,7 thiophanes simultaneously [3,2 c] pyridine hydrochloride | 太原理工大学 | 2017-08-18 | — | — | CN | claimed |
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | claimed |
| EP-2049548-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB Pharma, S.A. (BE) | 2009-04-22 | — | — | EP | claimed |
| EP-1891069-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B]PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | claimed |
| WO-2008012010-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB PHARMA, S.A. (BE) | 2008-01-31 | — | — | WO | claimed |
| EP-1268444-B1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-17 | — | — | EP | claimed |
| WO-2006125958-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4 , 5B] PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | claimed |
| US-6967197-B2 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-22 | — | — | US | claimed |
| US-6649608-B2 | Cyclin-dependent serine/threonine and focal adhesion kinase inhibitors | ASTRAZENECA AB (SE) | 2003-11-18 | — | — | US | claimed |
| JP-2003525278-A | — | — | 2003-08-26 | — | — | JP | claimed |
| US-20030149266-A1 | 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | claimed |
| US-20030134849-A1 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | US | claimed |
| EP-1268444-A1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | AstraZeneca AB (SE) | 2003-01-02 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001064655-A1 | 2, 4-DI(HETERO-)ARYLAMINO (-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2001-09-07 | — | — | WO | claimed |
| US-5494666-A | BETA-LACTAMASE INHIBITORS, ANTIBACTERIALS | HOFFMANN-LA ROCHE INC. (US) | 1996-02-27 | — | — | US | claimed |
| US-5464617-A | 1H-2,6a-diazacyclobut(cd)indene-6-carboxylic acid derivatives, antibiotics | HOFFMANN-LA ROCHE INC. (US) | 1995-11-07 | — | — | US | claimed |
| EP-0671401-A1 | Beta lactames | F. HOFFMANN-LA ROCHE AG (CH) | 1995-09-13 | — | — | EP | claimed |
| US-20200129458-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | AJINOMOTO CO., INC. (JP) | 2020-04-30 | — | — | US | disclosed |
| US-10221168-B1 | Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof | Wu, Xiao Hua (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221168-B1 | Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof | Wu, Xiao Hua (US) | 2019-03-05 | — | — | US | disclosed |
| EP-3438091-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | AJINOMOTO CO., INC. (JP) | 2019-02-06 | — | — | EP | disclosed |
| US-20190022039-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | AJINOMOTO CO., INC. (JP) | 2019-01-24 | — | — | US | disclosed |
| CN-107056801-B | A kind of synthetic method of 4,5,6,7- thiophane simultaneously [3,2-c] pyridine hydrochloride | 太原理工大学 | 2018-12-28 | — | — | CN | disclosed |
| CN-107056801-B | A kind of synthetic method of 4,5,6,7- thiophane simultaneously [3,2-c] pyridine hydrochloride | 太原理工大学 | 2018-12-28 | — | — | CN | disclosed |
| CN-107056801-A | A kind of synthetic method of 4,5,6,7 thiophanes simultaneously [3,2 c] pyridine hydrochloride | 太原理工大学 | 2017-08-18 | — | — | CN | disclosed |
| CN-107056801-A | A kind of synthetic method of 4,5,6,7 thiophanes simultaneously [3,2 c] pyridine hydrochloride | 太原理工大学 | 2017-08-18 | — | — | CN | disclosed |
| US-9540392-B2 | Thienopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-10 | — | — | US | disclosed |
| US-9540392-B2 | Thienopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-10 | — | — | US | disclosed |
| EP-2852596-B1 | THIENOPYRIMIDINES | Bayer Pharma AG (DE) | 2016-06-22 | — | — | EP | disclosed |
| US-20150133425-A1 | THIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | US | disclosed |
| US-20150133425-A1 | THIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | US | disclosed |
| US-20120149703-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVES | JITSUOKA MAKOTO (JP) | 2012-06-14 | — | — | US | disclosed |
| US-8163770-B2 | Benzoxathiin derivative | MSD. K. K. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8158791-B2 | Aza-substituted spiro derivatives | MSD K.K. (JP) | 2012-04-17 | — | — | US | disclosed |
| EP-2420502-A1 | FUSED PYRROLOPYRIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-7960402-B2 | Trans-5'-(2-fluoroethoxy)-3'-oxo-N-methyl-N-(2-piperidin-1-ylethyl)-spiro[cyclohexane-1,1'-(3'H)-isobenzofuran]-4-carboxamide hydrochloride; histamine H3 receptor antagonist or inverse agonist; metabolic disorders; circulatory diseases; nervous system diseases; psychological disorders; sleep disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7960394-B2 | 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20100168156-A1 | Novel Benzoxathiine Derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-7700628-B2 | Aromatic ether derivatives useful as thrombin inhibitors | ELI LILLY AND COMPANY (US) | 2010-04-20 | — | — | US | disclosed |
| US-7666866-B2 | Antithrombotic diamides | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| EP-1817287-B1 | AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS | LILLY CO ELI (US) | 2010-02-10 | — | — | EP | disclosed |
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | disclosed |
| US-20090258871-A1 | Aza-Substituted Spiro Derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-10-15 | — | — | US | disclosed |
| US-20090227566-A1 | AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
| EP-1819693-B1 | ANTITHROMBOTIC DIAMIDES | LILLY CO ELI (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20090186871-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-07-23 | — | — | US | disclosed |
| EP-1795527-B1 | CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2009-04-22 | — | — | EP | disclosed |
| EP-2049548-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB Pharma, S.A. (BE) | 2009-04-22 | — | — | EP | disclosed |
| US-20090062271-A1 | Antithrombotic Diamides | ELI LILLY AND COMPANY (US) | 2009-03-05 | — | — | US | disclosed |
| US-20080275069-A1 | Quinazoline Derivative | MSD K.K. (JP) | 2008-11-06 | — | — | US | disclosed |
| EP-1953165-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20080171753-A1 | Carbamoyl-Substituted Spiro Derivative | MSD K.K. (JP) | 2008-07-17 | — | — | US | disclosed |
| EP-1944301-A1 | NOVEL BENZOXATHIIN DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-1891069-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B]PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2008012010-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB PHARMA, S.A. (BE) | 2008-01-31 | — | — | WO | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
| US-20070232654-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| EP-1819693-A1 | ANTITHROMBOTIC DIAMIDES | ELI LILLY AND COMPANY (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1817287-A1 | AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS | Eli Lilly and Company (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1795527-A1 | CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-06-13 | — | — | EP | disclosed |
| EP-1757594-A1 | QUINAZOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
| EP-1268444-B1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2006125958-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4 , 5B] PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006057868-A1 | ANTITHROMBOTIC DIAMIDES | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | disclosed |
| WO-2006057845-A1 | AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | disclosed |
| US-6967197-B2 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-22 | — | — | US | disclosed |
| US-6649608-B2 | Cyclin-dependent serine/threonine and focal adhesion kinase inhibitors | ASTRAZENECA AB (SE) | 2003-11-18 | — | — | US | disclosed |
| US-20030149266-A1 | 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | disclosed |
| US-20030134849-A1 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | US | disclosed |
| WO-2003018019-A2 | NEW USE OF CYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | WO | disclosed |
| EP-1268444-A1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | AstraZeneca AB (SE) | 2003-01-02 | — | — | EP | disclosed |
| EP-1259499-A1 | THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-27 | — | — | EP | disclosed |
| EP-0923539-B1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2002-06-05 | — | — | EP | disclosed |
| EP-1198172-A1 | USE OF N-SUBSTITUTED HETEROCYCLYLALKYLAMINES AS HERBICIDES AND NOVEL N-SUBSTITUTED THIENYLALKYLAMINES | Bayer Aktiengesellschaft (DE) | 2002-04-24 | — | — | EP | disclosed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | disclosed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | disclosed |
| EP-1184370-A2 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2002-03-06 | — | — | EP | disclosed |
| WO-2001064655-A1 | 2, 4-DI(HETERO-)ARYLAMINO (-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001060808-A1 | THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
| US-6274584-B1 | PEPTIDE DERIVATIVES; BIOAVAILABILITY; ENZYME RESISTANCE; MILK AND WOOL PRODUCTION | NOVO NORDISK A/S (DK) | 2001-08-14 | — | — | US | disclosed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | disclosed |
| WO-2000065916-A1 | USE OF N-SUBSTITUTED HETEROCYCLYLALKYLAMINES AS HERBICIDES AND NOVEL N-SUBSTITUTED THIENYLALKYLAMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-11-09 | — | — | WO | disclosed |
| US-6140338-A | FOR TREATING ACUTE INFLAMMATORY DISEASES, CHRONIC INFLAMMATORY DISEASES, ACQUIRED IMMUNE DEFICIENCY SYNDROME, CANCER, ISCHEMIC REFLOW DISORDER AND/OR ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL, CO., LTD. (JP) | 2000-10-31 | — | — | US | disclosed |
| US-6127354-A | FOR TREATMENT OF GROWTH DISORDERS OR TO STIMULATE PRODUCTION OF WOOL OR MILK | NOVO NORDISK A/S (DK) | 2000-10-03 | — | — | US | disclosed |
| EP-1021441-A1 | SUBSTITUTED 2,4-DIAMINO-1,3,5-TRIAZINE AND THEIR USE AS HERBICIDES | BAYER AG (DE) | 2000-07-26 | — | — | EP | disclosed |
| US-5939398-A | ANTIATHEROSCLEROSIS AGENTS | PFIZER INC. (US) | 1999-08-17 | — | — | US | disclosed |
| US-5922770-A | NOVEL COMPOUNDS THAT STIMULATE THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY | NOVO NORDISK A/S (DK) | 1999-07-13 | — | — | US | disclosed |
| EP-0923539-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1999-06-23 | — | — | EP | disclosed |
| EP-0916668-A1 | CHEMOKINE RECEPTOR ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-05-19 | — | — | EP | disclosed |
| WO-1999018100-A1 | SUBSTITUTED 2,4-DIAMINO-1,3,5-TRIAZINE AND THEIR USE AS HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-04-15 | — | — | WO | disclosed |
| WO-1998003473-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1998-01-29 | — | — | WO | disclosed |
| US-5494666-A | BETA-LACTAMASE INHIBITORS, ANTIBACTERIALS | HOFFMANN-LA ROCHE INC. (US) | 1996-02-27 | — | — | US | disclosed |
| US-5464617-A | 1H-2,6a-diazacyclobut(cd)indene-6-carboxylic acid derivatives, antibiotics | HOFFMANN-LA ROCHE INC. (US) | 1995-11-07 | — | — | US | disclosed |
| EP-0671401-A1 | Beta lactames | F. HOFFMANN-LA ROCHE AG (CH) | 1995-09-13 | — | — | EP | disclosed |
| EP-0324610-A2 | Thieno[2,3-d]azepine derivatives, process for their preparation and pharmaceutical compositions containing them | LILLY INDUSTRIES LIMITED (GB) | 1989-07-19 | — | — | EP | disclosed |
| EP-0324610-A2 | Thieno[2,3-d]azepine derivatives, process for their preparation and pharmaceutical compositions containing them | LILLY INDUSTRIES LIMITED (GB) | 1989-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129458-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | GLP1R, GPR119, GIPR | NPC1 993/4885RAB9A 2322/4885SMN1; SMN2 3136/4885 |
| US-20120149703-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVES | AZI2, NR3C2, DNMT3A | NPC1 2544/4885RAB9A 232/4885SMN1; SMN2 2340/4885 |
| US-20100168156-A1 | Novel Benzoxathiine Derivative | XDH, GPR119, BRIX1 | NPC1 3375/4885RAB9A 3100/4885SMN1; SMN2 3660/4885 |
| US-20190022039-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | GLP1R, GPR119, GIPR | NPC1 993/4885RAB9A 2322/4885SMN1; SMN2 3136/4885 |
| US-20030149266-A1 | 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents | CDK2, CCNI, CDK1 | NPC1 4853/4885RAB9A 1426/4885SMN1; SMN2 1728/4885 |
| US-20070238734-A1 | JNK INHIBITORS | MAP3K7, MAPKAPK2, MAPK7 | NPC1 1098/4885RAB9A 2046/4885SMN1; SMN2 3785/4885 |
| US-20070232654-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | CTSS, CTSB, CTSE | NPC1 37/4885RAB9A 512/4885SMN1; SMN2 3350/4885 |
| US-20080275069-A1 | Quinazoline Derivative | HRH3, HRH4, HRH2 | NPC1 1762/4885RAB9A 1763/4885SMN1; SMN2 3325/4885 |
| US-20090062271-A1 | Antithrombotic Diamides | TFPI, SERPINC1, TFPI2 | NPC1 4370/4885RAB9A 2768/4885SMN1; SMN2 3805/4885 |
| US-20150133425-A1 | THIENOPYRIMIDINES | TYMP, DPYD, TYMS | NPC1 2809/4885RAB9A 3756/4885SMN1; SMN2 1664/4885 |
| US-10221168-B1 | Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof | MAN2A1, MAN1B1, ALG1 | NPC1 1159/4885RAB9A 1295/4885SMN1; SMN2 92/4885 |
| US-20030134849-A1 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | MMP9, MMP1, MMP3 | NPC1 3935/4885RAB9A 3292/4885SMN1; SMN2 3844/4885 |
| US-20080171753-A1 | Carbamoyl-Substituted Spiro Derivative | HRH3, HRH4, HRH2 | NPC1 1389/4885RAB9A 332/4885SMN1; SMN2 1350/4885 |
| US-20090186871-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | NPC1 3029/4885RAB9A 2681/4885SMN1; SMN2 4767/4885 |
| US-20090227566-A1 | AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS | TFPI, F2, F11 | NPC1 2610/4885RAB9A 2470/4885SMN1; SMN2 4751/4885 |
| US-20090258871-A1 | Aza-Substituted Spiro Derivatives | AZI2, NR3C2, DNMT3A | NPC1 2544/4885RAB9A 232/4885SMN1; SMN2 2340/4885 |
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | HRH3, HRH4, HRH2 | NPC1 3536/4885RAB9A 3681/4885SMN1; SMN2 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.